Prognostic Value of Serum Epstein-Barr Virus Antibodies and Their Correlation with TNM Classification in Patients with Locoregionally Advanced Nasopharyngeal Carcinoma

PURPOSE: This study assessed the correlation between Epstein-Barr virus (EBV) biomarkers and the eighth American Joint Committee on Cancer staging system and the prognostic values of IgG antibodies against replication and transcription activator (Rta-IgG), IgA antibodies against Epstein-Barr nuclear antigen 1, and BamH1 Z transactivator (Zta-IgA) in locoregionally advanced nasopharyngeal carcinoma (NPC) patients.

MATERIALS AND METHODS: Serum EBV antibody levels were measured by enzyme-linked immunosorbent assay in 435 newly diagnosed stage III-IVA NPC patients administered intensity-modulated radiation therapy±chemotherapy. The primary endpoint was progression-free survival (PFS).

RESULTS: Rta-IgG and Zta-IgA levels were positively correlated with the N category and clinical stage. Patients with high Rta-IgG levels (> 29.07 U/mL) showed a significantly inferior prognosis as indicated by PFS (77% vs. 89.8%, p=0.004), distant metastasis-free survival (DMFS) (88.3% vs. 95.8%, p=0.021), and local recurrence-free survival (LRFS) (91.2% vs. 98.3%, p=0.009). High Rta-IgG levels were also significantly associated with inferior PFS and LRFS in multivariable analyses. In the low-level EBV DNA group (≤ 1,500 copies/mL), patients with high Rta-IgG levels had significantly inferior PFS and DMFS (both p < 0.05). However, in the high-level EBV DNA group, Rta-IgG levels were not significantly associated with PFS, DMFS, and LRFS. In the advanced T category (T3-4) subgroup, high Rta-IgG levels were also significantly associated with inferior PFS, DMFS, and LRFS (both p < 0.05).

CONCLUSION: Rta-IgG and Zta-IgA levels were strongly correlated with the TNM classification. Rta-IgG level was a negative prognostic factor in locoregionally advanced NPC patients, especially those with advanced T category or low EBV DNA level.

Medienart:

E-Artikel

Erscheinungsjahr:

2021

Erschienen:

2021

Enthalten in:

Zur Gesamtaufnahme - volume:53

Enthalten in:

Cancer research and treatment - 53(2021), 4 vom: 20. Okt., Seite 991-1003

Sprache:

Englisch

Beteiligte Personen:

Zhang, Wan-Ru [VerfasserIn]
Du, Yu-Yun [VerfasserIn]
Guo, Chun-Yan [VerfasserIn]
Zhou, Han-Xing [VerfasserIn]
Lin, Jie-Yi [VerfasserIn]
Meng, Xiao-Han [VerfasserIn]
Mo, Hao-Yuan [VerfasserIn]
Luo, Dong-Hua [VerfasserIn]

Links:

Volltext

Themen:

Antibodies, Viral
Biomarkers, Tumor
EBV-encoded nuclear antigen 1
Epstein–Barr virus antibodies
Epstein-Barr Virus Nuclear Antigens
Immunoglobulin A
Immunoglobulin G
Journal Article
Nasopharyngeal carcinoma
O5GA75RST7
Prognosis
TNM classification

Anmerkungen:

Date Completed 07.02.2022

Date Revised 27.04.2022

published: Print-Electronic

Citation Status MEDLINE

doi:

10.4143/crt.2020.1298

funding:

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

NLM320561674